Expanding First-Trimester Preterm Preeclampsia Screening With Placental Growth Factor Testing

Journal of Obstetrics and Gynaecology Canada 2026 Open access

Read full text
Authors: Nan Okun, Jo-Ann M. Johnson, Stefania Ronzoni, Tianhua Huang, Emmanuel Bujold
DOI: 10.1016/j.jogc.2026.103394
Cited by: 1
References: 9

Abstract

Preterm preeclampsia, which affects 0.5%-1% of pregnancies, can be prevented with aspirin initiated before 16 weeks. However, its effectiveness is highly dependent on adherence. Screening for preterm preeclampsia based on clinical factors alone is associated with a high number needed to treat (>100) and poor treatment adherence. Conversely, a review of current evidence shows that a multiple marker algorithm including placental growth factor and standardized blood pressure measurement is associated with lower number needed to treat (

Fields of Study & Subjects

Pregnancy and preeclampsia studies Maternal and fetal healthcare Gestational Diabetes Research and Management

Publication details

Journal / source
Journal of Obstetrics and Gynaecology Canada
Publisher
Elsevier BV
Volume
48
Issue
7
Pages
103394–103394
Publication date
14 May 2026
Language
EN